Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia Ongoing WARFARIN SODIUM 3 2231351 King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, Single Oral Dose, Open Label, Two Sequence, Two Treatment, Four Periods, Full Replicate Crossover Study to Determine the Bioequivalence of Azacitidine 300 mg Film Coated Tablets Versus Onureg® 300 mg Film Coated Tablets For Adult Patients with Acute Myeloid Leukaemia (AML) under Fasting Conditions Hikma Pharmaceuticals Ongoing Azacitidine 300 mg Film- Coated Tablets BE HIK-AZA-2023-01 King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease Vertex Pharmaceuticals Ongoing Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) 3 VX21-CTX001-161 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD Boehringer Ongoing BI 456906 3 1404-0040 King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah),King Saud Medical City (Riyadh)
Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors NovoNordisk Ongoing NNC0365-3769 B (Mim8) 3 NN7769-4532 King Faisal Specialist Hospital and Research Center (Riyadh)
A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma (OPERA) King Faisal Specialist Hospital & Research Centre ـJeddah, Saudi Arabia Ongoing Tyrosine Kinase inhibitors and Immunotherapy 4 OPERA2020 King Faisal Specialist Hospital and Research Center (Jeddah)
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Abbvie Ongoing Upadacitinib (Rinvoq) 3 M23-698 King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah)
A Phase 3, single-arm, multicenter, multinational, open label,one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX Sanofi Ongoing Fitusiran 3 EFC17574 King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz University Hospital (Jeddah)
A single arm, multicentre observational study to evaluate effectiveness of pegcetacoplan under real world conditions in patients with paroxysmal nocturnal hemoglobinuria (PNH) COMPLETE Sobi - Swedish Orphan Biovitrum AG Ongoing pegcetacoplan (ASPAVELI) 4 Sobi.PEGCE King Faisal Specialist Hospital and Research Center (Jeddah),King Faisal Specialist Hospital and Research Center (Riyadh),King Faisal Specialist Hospital and Research Center (Madinah)
The Effect of Black Seeds (Nigella Sativa) on Prediabetic Overweight and Obese Adolescents Imam Abdulrhman bin Faisal university Ongoing Nigella sativa seeds 3 2230500005 Family and Community Medicine Center (Dammam)
View 21 - 30 From 720